# Episode 442: The 2026 ACTRIMS Forum (Part 2) with Dr. Jeffrey Cohen, Dr. Daniel Ontaneda, and Kristine Werner Ozug

Page: https://stenobird.com/podcast/realtalk-ms-779631/episode-442-the-2026-actrims-forum-part-2-with-dr-jeffrey-cohen-dr-daniel-ontaneda-and-kristine-werner-ozug
Text version: https://stenobird.com/podcast/realtalk-ms-779631/episode-442-the-2026-actrims-forum-part-2-with-dr-jeffrey-cohen-dr-daniel-ontaneda-and-kristine-werner-ozug.md
Podcast: [RealTalk MS](https://stenobird.com/podcast/realtalk-ms-779631)
Published: 2026-02-16T18:00:00+00:00
Episode link: https://realtalkms.com/442
Audio file: https://traffic.libsyn.com/secure/realtalkms/Episode_442_The_2026_ACTRIMS_Forum_Part_2_with_Dr._Jeffrey_Cohen_Dr._Daniel_Ontaneda_and_Kristine_Werner_Ozug.mp3?dest-id=570470
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/realtalk-ms-779631/episodes/episode-442-the-2026-actrims-forum-part-2-with-dr-jeffrey-cohen-dr-daniel-ontaneda-and-kristine-werner-ozug
Duration seconds: 2681

## Resource

Welcome back to Part Two of our coverage of the 2026 ACTRIMS Forum. This week, we shift our focus to emerging therapies and clinical insights that are re-shaping the future of MS care. From the latest information on stem cell transplantation to evolving treatment strategies to the labels used to describe MS, we're breaking down the complex science into the conversations that matter most to the MS community. Joining me to discuss one of the most significant presentations from the 2026 ACTRIMS Forum is Dr. Jeffrey Cohen, who opened the event with the Kenneth P. Johnson Memorial Lecture. Dr. Cohen's lecture, "AHSCT: Current Status and Remaining Questions," tackled a topic of massive interest to both clinicians and the MS community: Autologous Hematopoietic Stem Cell Transplantation (AHSCT). Often described as "resetting" the immune system, AHSCT is a complex and life-changing procedure that continues to evolve. In our conversation, Dr. Cohen delves deeper into his lecture, discussing transplant efficacy, the best candidates for AHSCT, the optimal time to consider AHSCT, and how people living with MS may qualify to participate in a clinical trial comparing the benefits of AHSCT with those of high-efficacy disease-modifying therapies. Joining me for a deep dive into the future of MS care is Dr. Daniel Ontaneda. Our wide-ranging conversation explores the cutting edge of clinical practice and research, including the "early vs aggressive" treatment debate, how incorporating new imaging biomarkers will lead to faster, more reliable, and more accurate MS diagnoses, and whether the current disease classifications still serve the best interests of patient care. While MS research conferences like the ACTRIMS Forum are never short on world-class expert opinions and groundbreaking da…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/realtalk-ms-779631/episodes/episode-442-the-2026-actrims-forum-part-2-with-dr-jeffrey-cohen-dr-daniel-ontaneda-and-kristine-werner-ozug/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/realtalk-ms-779631/episode-442-the-2026-actrims-forum-part-2-with-dr-jeffrey-cohen-dr-daniel-ontaneda-and-kristine-werner-ozug.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.